Kenji Watanabe

TL;DR: This work shows that loss of REV7 in mouse and human cell lines re-establishes CTIP-dependent end resection of DSBs in BRCA1-deficient cells, leading to HR restoration and PARP inhibitor resistance, which is reversed by ATM kinase inhibition.

TL;DR: It is reported that human demethylase JMJD1C regulates the RAP80–BRCA1 branch of this DNA-damage response (DDR) pathway, identified as a DDR component, with implications for genome-integrity maintenance, tumorigenesis and cancer treatment.

TL;DR: A novel mechanism that orchestrates replication checkpoint signaling and ubiquitin-proteasome machinery with the DNA damage bypass pathway to guard against replication collapse under conditions of replication stress is defined.

TL;DR: TOPBP1 acts in homologous recombination repair, impacts the response to chemotherapeutic agent olaparib, and exhibits aberrant patterns in subsets of human ovarian carcinomas.

TL;DR: A novel activity of the FDA-approved antimalarial drug amodiaquine is reported which inhibits rRNA transcription, a rate-limiting step for ribosome biogenesis, in a dose-dependent manner, revealing an unsuspected activity of a drug approved and used in the clinics for over 30 years.